Format

Send to

Choose Destination
Mol Imaging Biol. 2016 Oct;18(5):637-50. doi: 10.1007/s11307-016-0993-2.

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany.

Author information

1
Department of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia.
2
Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls-Universität, Tübingen, Germany.
3
Department of Interventional and Diagnostic Radiology, Eberhard-Karls-Universität, Tübingen, Germany.
4
Department of Nuclear Medicine, University Clinic, Leipzig, Germany.
5
Department of Nuclear Medicine, Ulm University, Ulm, Germany.
6
Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK.
7
Moffitt Cancer Center, Tampa, USA.
8
Division of Imaging Sciences and Biomedical Engineering, Department of Cancer Imaging, King's College London, London, UK.
9
Department of Nuclear Medicine, Radboud University, Nijmegen, The Netherlands.
10
Peter MacCallum Cancer Centre, Melbourne, Australia.
11
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
12
Division of Nuclear Medicine and clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany.
13
ZEMODI, Zentrum für Moderne Diagnostik, Bremen, Germany.
14
Department of Nuclear Medicine, Technical University Munich, Munich, Germany.
15
Strategy and Innovation Technology Center, Siemens Healthcare GmbH, Erlangen, Germany.
16
Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven - University of Leuven, Leuven, Belgium.
17
Philips, 3000 Minuteman Road, Andover, MA, 01810, USA.
18
Department of Diagnostic Radiology, Radiation Sciences, Umeå University/Norrlands University Hospital, Umeå, Sweden.
19
Nuclear Medicine Unit, Departments of Medical-Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy.
20
Department of Nuclear Medicine, University Hospital Münster and European Institute for Molecular Imaging, University of Münster, Münster, Germany.
21
Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada.
22
GE Healthcare, PET/MR, Milwaukee, USA.
23
Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland.
24
Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
25
Department of Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland.
26
Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.beyer@meduniwien.ac.at.

Abstract

This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tübingen, Germany, from February 15 to 19, 2016. Specifically, we summarise the second part of the workshop made up of invited presentations from active researchers in the field of PET/MRI and associated fields augmented by round table discussions and dialogue boards with specific topics. This year, this included practical advice as to possible approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To address perceived challenges still remaining to innovatively integrate PET and MRI system technologies, a dedicated round table session brought together key representatives from industry and academia who were engaged with either the conceptualisation or early adoption of hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual information which will enable not only overall disease detection but also disease characterisation would eventually be regarded as compelling arguments for the adoption of PET/MR. However, as indicated by previous workshops, evidence in favour of this observation is only growing slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as different systems and sites. The participants emphasised that moving from status quo to status go entails the need to adopt standardised imaging procedures and the readiness to act together prospectively across multiple PET/MRI sites and vendors.

KEYWORDS:

Attenuation correction; Cardiology; Combined imaging; MRI; Molecular imaging; Multi-parametric imaging; Neurology; Oncology; PET; PET/CT; PET/MRI; Quantification

PMID:
27534971
PMCID:
PMC5010606
DOI:
10.1007/s11307-016-0993-2
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Compliance with ethical standardsConflict of interestThomas Beyer is part of a Siemens collaboration activity that supports a PhD student for the duration of 3 years.Dale Bailey is part of a Siemens collaboration activity in SPECT/CT that supports a PhD student for the duration of 3 years.Rupert Lanzenberger is the recipient of travel grants and speaker honoraria from AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, and Roche Austria GmbH.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center